On Monday, Krystal Biotech hit a key performance benchmark, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 82, up from 79 the day before.
IBD's unique RS Rating tracks technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks tend to have an RS Rating north of 80 as they begin their biggest climbs.
Looking For The Best Stocks To Buy And Watch? Start Here
Krystal Biotech is working on a consolidation with a 219.34 entry. See if the stock can clear the breakout price in heavy trade.
Krystal Biotech posted 0% EPS growth in its most recent report. Sales gains came in at 879%. The next quarterly numbers are expected on or around Nov. 4.
Krystal Biotech earns the No. 34 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
